Targanta Seeks $86M In IPO For Antibiotic Development
As it prepares to file a new drug application for the antibiotic oritavancin in the first quarter of 2008, Targanta Therapeutics Corp. filed to raise $86.25 million in an initial public offering. (BioWorld Today)
